Roivant Sciences (ROIV) Q2 2026 earnings summary

Executive summary

• Achieved significant clinical milestones, including positive Phase 3 VALOR data for brepocitinib in dermatomyositis (DM) and durable, disease-modifying results for batoclimab in Graves' disease, positioning the pipeline for multiple blockbuster indications.

• Advanced a robust late-stage pipeline with 11 registrational trials across multiple indications, including DM, non-infectious uveitis, Graves' disease, myasthenia gravis, and others.

• Maintained a strong capital position with $4.4 billion in cash and cash equivalents and no debt as of September 30, 2025.

• Completed major divestitures (Dermavant, Telavant), resulting in significant cash inflows and supporting future growth.

• Investor Day scheduled for December 11, 2025, to provide a comprehensive update on future strategy and commercial opportunities.

Financial highlights

• Reported a net loss from continuing operations of $166 million for Q2 2025 and $440 million for the six months ended September 30, 2025.

• R&D expenses rose to $164.6M for Q2 2025 and $317.5M for the six months, mainly due to anti-FcRn and brepocitinib programs.

• G&A expenses decreased to $143.1M for Q2 2025, reflecting lower personnel costs after one-time retention awards.

• Cash, cash equivalents, and marketable securities totaled $4.4B as of September 30, 2025.

• Share repurchase program authorized for $500M after completing a prior $1.5B program.

Outlook and guidance

• NDA filing for brepocitinib in DM planned for H1 2026, with potential approval and launch in H2 2026.

• Multiple pivotal and registrational trial readouts expected through 2026–2028, including for batoclimab, IMVT-1402, and mosliciguat.

• Cash runway expected to support operations into profitability.

• Ongoing focus on in-licensing and acquisition of new assets to expand the pipeline.

• Investor Day scheduled for December 11, 2025.